Small Interfering RNA (siRNA) Therapeutics Market Growth (2026-2033) | RNA Drugs, RNA Interference, Gene Silencing & Japan Growth Expansion

DataM Intelligence has released a new research report titled "Small Interfering RNA (siRNA) Therapeutics Market Size 2026" The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the global Small Interfering RNA (siRNA) Therapeutics market.

Ready to scale in the Small Interfering RNA (siRNA) Therapeutics Market? Connect with the right partners and unlock new growth opportunities today:- https://www.datamintelligence.com/partner-identification-enquiry/small-interfering-rna-therapeutics-market?kb

Top siRNA Therapies Driving Strong U.S. Revenue Growth in 2024

• Amvuttra generated US$ 970.45 million in global sales in 2024, with U.S. revenue reaching US$ 630.61 million, accounting for a 64.98% market share.

• Leqvio recorded US$ 754.00 million in global sales in 2024, including US$ 385.00 million from the U.S., representing a 51.06% share.

• Givlaari achieved US$ 255.87 million in worldwide sales in 2024, with U.S. sales contributing US$ 165.37 million, or 64.63% of total revenue.

• Onpattro reported US$ 252.85 million in global sales in 2024, of which US$ 74.78 million came from the U.S., representing a 29.57% share.

• Oxlumo generated US$ 167.05 million globally in 2024, with U.S. revenue totaling US$ 62.76 million, accounting for 37.57% of sales.

Download Free Sample Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/small-interfering-rna-therapeutics-market?kb

List of Key Players 2026:

Alnylam Pharmaceuticals, Inc., Novartis AG, and Novo Nordisk A/S.

Emerging Players in (2025):

Arbutus Biopharma, ADARx Pharmaceuticals, Arrowhead Pharmaceuticals, Inc., and Amgen Inc

United States: Recent Industry Developments

✅ March 2026: Alnylam Pharmaceuticals advanced commercialization efforts for RNAi therapeutics targeting rare genetic and cardiovascular diseases across the U.S. market.

✅ February 2026: Arrowhead Pharmaceuticals expanded clinical development programs for next-generation siRNA therapies focused on liver and pulmonary disorders.

✅ January 2026: Dicerna Pharmaceuticals (Novo Nordisk) strengthened research activities in GalXCTM RNAi technology for chronic cardiometabolic disease treatment applications.

✅ December 2025: Ionis Pharmaceuticals accelerated partnerships and pipeline expansion for RNA-targeted therapeutics addressing neurological and rare diseases.

Growth Forecast Projected 2026:

The Global Small Interfering RNA (siRNA) Therapeutics Market is anticipated to rise at a considerable rate during the forecast period, between 2026 and 2033. In 2025, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Key Developments 2025-2026:

✅ April 2026: Biopharmaceutical companies accelerated development of next-generation siRNA therapeutics with enhanced targeting capabilities, improved stability, and longer-lasting gene-silencing effects for chronic disease management.

✅ March 2026: Strategic collaborations increased between biotechnology firms and pharmaceutical companies to advance RNAi drug pipelines and expand clinical applications in liver diseases, cardiovascular disorders, and oncology.

✅ February 2026: Advancements in lipid nanoparticle (LNP) and conjugate delivery technologies improved tissue-specific delivery efficiency and reduced off-target effects in siRNA-based therapies.

✅ January 2026: Regulatory and clinical progress in RNA interference therapeutics supported broader investment activity and strengthened commercialization opportunities for rare genetic disease treatments.

✅ December 2025: Manufacturers expanded RNA therapeutic production capabilities to support growing clinical trial activity and increasing demand for scalable nucleic acid manufacturing solutions.

✅ November 2025: Research institutions and biotechnology companies intensified development of personalized siRNA therapeutics targeting previously undruggable genes and mutation-specific disease pathways.

✅ October 2025: Rising adoption of precision medicine approaches and growing investments in RNA-based drug discovery accelerated innovation in siRNA therapeutic platforms globally.

How Our Market Research Process Works:

The global Small Interfering RNA (siRNA) Therapeutics Market research report is developed using a comprehensive combination of primary and secondary data sources. The study evaluates a wide range of industry-influencing factors, including government regulations, evolving market dynamics, competitive intensity, and historical performance trends. It also analyzes technological advancements, emerging innovations, and developments across related industries. In addition, the report assesses market volatility, growth opportunities, potential barriers, and key challenges that could impact the future expansion of the Small Interfering RNA (siRNA) Therapeutics ecosystem.

Recent Mergers & Acquisitions (M & A) 2025-2026:

• April 2026: BioMarin Pharmaceutical completed the acquisition of Amicus Therapeutics
to strengthen its rare disease and RNA-based therapeutics portfolio.

• February 2026: Frontier Biotechnologies entered a global exclusive licensing agreement with GSK for two siRNA therapeutics targeting kidney diseases in a deal valued at up to US$1 billion.

• February 2026: Suzhou Ribo Life Science and Madrigal Pharmaceuticals
signed a global licensing deal for six preclinical siRNA programs focused on MASH therapies.

• January 2026: Bayer announced a strategic collaboration and global licensing agreement with Soufflé Therapeutics
to advance heart-targeted siRNA therapeutics for dilated cardiomyopathy.

• January 2026: GSK agreed to acquire RAPT Therapeutics
in a US$2.2 billion deal aimed at expanding its immunology and advanced therapeutics pipeline.

Request Strategic Market Customization: https://datamintelligence.com/customize/small-interfering-rna-therapeutics-market?kb

Japan: Recent Industry Developments
✅ March 2026: Takeda Pharmaceutical Company Limited increased investment in RNA-based therapeutics research to support precision medicine and rare disease treatment development.

✅ February 2026: Nippon Shinyaku Co., Ltd. expanded collaborative research activities focused on nucleic acid therapeutics and advanced drug delivery technologies.

✅ January 2026: Daiichi Sankyo Company, Limited strengthened RNA therapeutics pipeline initiatives targeting oncology and chronic disease applications.

✅ December 2025: Otsuka Pharmaceutical Co., Ltd. advanced innovation programs in gene-silencing therapeutics to support next-generation precision healthcare solutions.

Major Focused Key Segmentations 2026:

By Drug: Patisiran, Givosiran, Lumasiran, Inclisiran, Nedosiran, Vutrisiran, Others

By Indication: Transthyretin Amyloidosis, Acute Hepatic Porphyria, Primary Hyperoxaluria Type 1, Primary Hyperlipidemia, Others

By Route of Administration: Intravenous, Subcutaneous

Regional Growth Analysis for Market:

⇥ North America: 52.2% - Dominates the Small Interfering RNA (siRNA) Therapeutics Market due to strong biotechnology investments, advanced healthcare infrastructure, and increasing RNA-based drug approvals.

⇥ Europe: 24.6% - Growth supported by rising clinical research activities, government funding, and expanding precision medicine initiatives.

⇥ Asia-Pacific: 15.4% - Rapidly expanding through increasing biopharmaceutical manufacturing, healthcare investments, and growing adoption of advanced therapeutics.

⇥ Middle East & Africa: 4.3% - Emerging market driven by improving healthcare infrastructure and rising awareness of innovative therapies.

⇥ South America: 3.5% - Steady development supported by expanding pharmaceutical research and increasing access to advanced treatment options.

We Provide Benefits of the Report:

Chapter 1: Lays the foundation by defining the scope of the report, highlighting core market segments across regions, product types, and applications. It delivers a clear snapshot of current market size, growth potential, and how the industry is expected to evolve in both the near and long term.

Chapter 2: Spotlights the most impactful market insights, unveiling the transformative trends and forces shaping the future of the industry.

Chapter 3: Provides a deep dive into the competitive landscape of , covering revenue shares, strategic initiatives, and notable mergers & acquisitions that are reshaping the market.

Chapter 4: Presents detailed company profiles of leading players featuring financial performance, product portfolios, profit margins, and key milestones that set them apart in the industry.

Chapters 5 & 6: Break down revenue analysis at both regional and country levels, offering precise data on market size, growth drivers, and expansion opportunities across global markets.

Chapter 7: Analyzes the market by product type, spotlighting segment-specific opportunities and helping stakeholders identify untapped, high-growth areas.

Chapter 8 :Explores the market through application-based segmentation, assessing demand across industries and pinpointing downstream sectors with the strongest potential for growth.

Chapter 9: Maps the industry's supply chain in detail, tracing upstream and downstream activities to provide clarity on value creation across the ecosystem.

Chapter 10: Wraps up with a concise summary of the report's key insights distilling the most critical findings and strategic takeaways for decision-makers and stakeholders.

Unlock Full 360° Strategic Report: https://www.datamintelligence.com/buy-now-page?report=small-interfering-rna-therapeutics-market?kb

FAQ

Q1: What is the current size of the Small Interfering RNA (siRNA) Therapeutics Market?

A: The Small Interfering RNA (siRNA) Therapeutics Market was valued at US$ 2.99 billion in 2025 and is forecasted to hit US$ 14.54 billion by 2033

Q2: How rapidly will the Market expanding?

A: The Small Interfering RNA (siRNA) Therapeutics market is projected to grow at a CAGR of 17.4% between 2026 and 2033.

Get Unlimited Market Reports & Strategic Insights: https://www.datamintelligence.com/reports-subscription?kb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.